Patel Sanj K
Insider CIK 1532218 · ICPT Director · SYRS Director · KNSA Chairman & CEO, Director · BCRX Director · GEVA President & CEO, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 30,050 | — | $0 | 30,050 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 120,150 | — | $0 | 120,150 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 8,609 | — | $0 | 25,826 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 6,237 | — | $0 | 12,475 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 9,991 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 6,481 | — | $0 | 6,481 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 6,481 | — | $0 | 6,481 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 9,991 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 6,237 | — | $0 | 12,475 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 8,609 | — | $0 | 25,826 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 120,150 | — | $0 | 120,150 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 30,050 | — | $0 | 30,050 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 9,991 | — | $0 | 86,165 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 6,481 | — | $0 | 92,646 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2026-09-01 | 2026-09-03 | 15,144 | $79.28 | $1.20M | 92,348 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 8,609 | — | $0 | 107,492 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 6,237 | — | $0 | 98,883 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 8,609 | — | $0 | 107,492 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 9,991 | — | $0 | 86,165 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 6,481 | — | $0 | 92,646 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2026-09-01 | 2026-09-03 | 15,144 | $79.28 | $1.20M | 92,348 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 6,237 | — | $0 | 98,883 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 9,991 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 6,481 | — | $0 | 6,481 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 6,237 | — | $0 | 12,475 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 8,609 | — | $0 | 25,826 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 120,150 | — | $0 | 120,150 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 30,050 | — | $0 | 30,050 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2026-09-01 | 2026-09-03 | 15,144 | $79.28 | $1.20M | 92,348 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 8,609 | — | — | 107,492 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 6,237 | — | — | 98,883 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 6,481 | — | — | 92,646 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 9,991 | — | — | 86,165 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 9,991 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 6,481 | — | $0 | 6,481 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 6,237 | — | $0 | 12,475 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-09-01 | 2026-09-03 | 8,609 | — | $0 | 25,826 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 120,150 | — | $0 | 120,150 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-09-01 | 2026-09-03 | 30,050 | — | $0 | 30,050 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2026-09-01 | 2026-09-03 | 15,144 | $79.28 | $1.20M | 92,348 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 8,609 | — | — | 107,492 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 6,237 | — | — | 98,883 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 6,481 | — | — | 92,646 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-09-01 | 2026-09-03 | 9,991 | — | — | 86,165 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | C Conversion deriv | 2026-06-01 | 2026-06-02 | 900,000 | — | $0 | 626,160 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | C Conversion | 2026-06-01 | 2026-06-02 | 900,000 | — | $0 | 951,794 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-05-01 | 2026-05-01 | 48,565 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2026-05-01 | 2026-05-01 | 48,565 | $54.02 | $2.62M | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-05-01 | 2026-05-01 | 48,565 | $30.93 | $1.50M | 48,565 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-30 | 2026-04-30 | 2,141 | — | $0 | 48,565 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-04-30 | 2026-04-30 | 2,141 | $30.93 | $66.2K | 2,141 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2026-04-30 | 2026-04-30 | 2,141 | $54.01 | $115.6K | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-29 | 2026-04-30 | 22,544 | — | $0 | 50,706 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-04-29 | 2026-04-30 | 22,544 | $30.93 | $697.3K | 22,544 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2026-04-29 | 2026-04-30 | 22,544 | $54.01 | $1.22M | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-28 | 2026-04-30 | 431,904 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-28 | 2026-04-30 | 51,750 | — | $0 | 73,250 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-04-28 | 2026-04-30 | 431,904 | $10.36 | $4.47M | 431,904 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-04-28 | 2026-04-30 | 51,750 | $30.93 | $1.60M | 483,654 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2026-04-28 | 2026-04-30 | 74,635 | $50.43 | $3.76M | 409,019 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2026-04-28 | 2026-04-30 | 113,673 | $51.47 | $5.85M | 295,346 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2026-04-28 | 2026-04-30 | 243,596 | $52.02 | $12.67M | 51,750 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2026-04-28 | 2026-04-30 | 51,750 | $54.02 | $2.80M | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-07 | 2026-04-08 | 9,991 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-04-07 | 2026-04-08 | 9,991 | — | $0 | 81,005 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2026-04-07 | 2026-04-08 | 4,831 | $48.94 | $236.4K | 76,174 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-06 | 2026-04-08 | 7,278 | — | $0 | 431,904 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-04-06 | 2026-04-08 | 7,278 | $10.36 | $75.4K | 7,278 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2026-04-06 | 2026-04-08 | 7,278 | $50.01 | $364.0K | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-01 | 2026-04-03 | 6,481 | — | $0 | 6,481 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-04-01 | 2026-04-03 | 120,150 | — | $0 | 120,150 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-04-01 | 2026-04-03 | 30,050 | — | $0 | 30,050 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2026-04-01 | 2026-04-03 | 60,100 | — | $0 | 60,100 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-01 | 2026-04-03 | 6,237 | — | $0 | 12,475 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2026-04-01 | 2026-04-03 | 8,609 | — | $0 | 25,826 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2026-04-01 | 2026-04-03 | 10,313 | $48.13 | $496.4K | 71,014 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2026-04-01 | 2026-04-03 | 21,327 | — | $0 | 81,327 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | G Gift | 2025-11-13 | 2025-11-14 | 60,000 | — | $0 | 60,000 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | G Gift | 2025-11-13 | 2025-11-14 | 60,000 | — | $0 | 51,794 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | G Gift | 2025-11-12 | 2025-11-14 | 111,794 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | G Gift | 2025-11-12 | 2025-11-14 | 111,794 | — | $0 | 111,794 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-10-22 | 2025-10-22 | 97,390 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-10-22 | 2025-10-22 | 97,390 | $3.80 | $370.1K | 209,184 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-10-22 | 2025-10-22 | 97,390 | $38.83 | $3.78M | 111,794 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-10-21 | 2025-10-22 | 39,331 | — | $0 | 97,390 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-10-21 | 2025-10-22 | 39,331 | $38.77 | $1.52M | 111,794 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-10-21 | 2025-10-22 | 39,331 | $3.80 | $149.5K | 151,125 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-10-20 | 2025-10-22 | 121,248 | — | $0 | 136,721 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-10-20 | 2025-10-22 | 22,314 | $39.32 | $877.4K | 111,794 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-10-20 | 2025-10-22 | 98,934 | $38.81 | $3.84M | 134,108 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-10-20 | 2025-10-22 | 121,248 | $3.80 | $460.7K | 233,042 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-09-02 | 2025-09-03 | 6,569 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-09-02 | 2025-09-03 | 3,177 | $34.28 | $108.9K | 111,794 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-09-02 | 2025-09-03 | 6,569 | — | $0 | 114,971 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-09-01 | 2025-09-03 | 9,992 | — | $0 | 9,991 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-09-01 | 2025-09-03 | 6,481 | — | $0 | 12,962 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-09-01 | 2025-09-03 | 137,638 | — | $0 | 137,638 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-09-01 | 2025-09-03 | 34,435 | — | $0 | 34,435 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-09-01 | 2025-09-03 | 6,238 | — | $0 | 18,712 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-09-01 | 2025-09-03 | 9,992 | — | $0 | 119,385 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-09-01 | 2025-09-03 | 6,481 | — | $0 | 109,393 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-09-01 | 2025-09-03 | 6,238 | — | $0 | 102,912 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-09-01 | 2025-09-03 | 10,983 | $33.49 | $367.8K | 108,402 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-28 | 2025-05-28 | 62,116 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-28 | 2025-05-28 | 62,116 | $1.59 | $98.8K | 158,790 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-05-28 | 2025-05-28 | 62,116 | $27.33 | $1.70M | 96,674 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-27 | 2025-05-28 | 19,317 | — | $0 | 62,116 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-05-27 | 2025-05-28 | 19,317 | $27.01 | $521.8K | 96,674 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-27 | 2025-05-28 | 19,317 | $1.59 | $30.7K | 115,991 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-23 | 2025-05-28 | 4,837 | — | $0 | 81,433 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-05-23 | 2025-05-28 | 4,837 | $27.00 | $130.6K | 96,674 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-23 | 2025-05-28 | 4,837 | $1.59 | $7.7K | 101,511 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-20 | 2025-05-22 | 2,349 | — | $0 | 86,270 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-20 | 2025-05-22 | 2,349 | $1.59 | $3.7K | 99,023 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-05-20 | 2025-05-22 | 2,349 | $27.02 | $63.5K | 96,674 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-13 | 2025-05-15 | 2,872 | — | $0 | 88,619 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-05-13 | 2025-05-15 | 2,872 | $27.03 | $77.6K | 96,674 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-13 | 2025-05-15 | 2,872 | $1.59 | $4.6K | 99,546 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-09 | 2025-05-09 | 6,029 | — | $0 | 91,491 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-05-09 | 2025-05-09 | 6,029 | $27.05 | $163.1K | 96,674 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-09 | 2025-05-09 | 6,029 | $1.59 | $9.6K | 102,703 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-08 | 2025-05-09 | 101 | — | $0 | 97,520 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-05-08 | 2025-05-09 | 101 | $27.00 | $2.7K | 96,674 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-08 | 2025-05-09 | 101 | $1.59 | $161 | 96,775 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-05-07 | 2025-05-09 | 1,965 | — | $0 | 97,621 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-05-07 | 2025-05-09 | 1,965 | $1.59 | $3.1K | 98,639 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2025-05-07 | 2025-05-09 | 1,965 | $27.00 | $53.1K | 96,674 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-05-01 | 2025-05-05 | 8,386 | — | $0 | 8,386 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-05-01 | 2025-05-05 | 7,987 | — | $0 | 7,987 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-05-01 | 2025-05-05 | 12,910 | — | $0 | 12,910 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-05-01 | 2025-05-05 | 13,328 | — | $0 | 26,238 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-04-07 | 2025-04-09 | 9,992 | — | $0 | 9,991 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-04-07 | 2025-04-09 | 4,832 | $20.28 | $98.0K | 96,674 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-04-07 | 2025-04-09 | 9,992 | — | $0 | 101,506 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-04-01 | 2025-04-03 | 68,869 | — | $0 | 68,869 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-04-01 | 2025-04-03 | 6,481 | — | $0 | 12,962 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-04-01 | 2025-04-03 | 6,238 | — | $0 | 18,712 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-04-01 | 2025-04-03 | 34,435 | — | $0 | 34,435 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2025-04-01 | 2025-04-03 | 137,638 | — | $0 | 137,638 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-04-01 | 2025-04-03 | 6,481 | — | $0 | 90,597 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-04-01 | 2025-04-03 | 6,238 | — | $0 | 96,835 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-04-01 | 2025-04-03 | 2,304 | $21.77 | $50.2K | 94,531 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-04-01 | 2025-04-03 | 3,017 | $21.77 | $65.7K | 91,514 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2025-03-16 | 2025-03-19 | 6,569 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2025-03-16 | 2025-03-19 | 6,569 | — | $0 | 86,120 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2025-03-16 | 2025-03-19 | 2,004 | $22.61 | $45.3K | 84,116 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2024-11-06 | 2024-11-08 | 89,561 | — | $0 | 10,025 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2024-11-06 | 2024-11-08 | 89,561 | $23.00 | $2.06M | 79,551 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2024-11-06 | 2024-11-08 | 89,561 | $1.59 | $142.4K | 169,112 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2024-09-02 | 2024-09-04 | 6,569 | — | $0 | 6,569 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2024-09-02 | 2024-09-04 | 6,569 | — | $0 | 82,728 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2024-09-02 | 2024-09-04 | 3,177 | $26.74 | $85.0K | 79,551 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2024-09-01 | 2024-09-04 | 9,992 | — | $0 | 19,983 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2024-09-01 | 2024-09-04 | 6,482 | — | $0 | 19,443 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2024-09-01 | 2024-09-04 | 129,750 | — | $0 | 129,750 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | A Award deriv | 2024-09-01 | 2024-09-04 | 24,950 | — | $0 | 24,950 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | F Tax w/h | 2024-09-01 | 2024-09-04 | 7,967 | $26.74 | $213.0K | 76,159 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2024-09-01 | 2024-09-04 | 16,474 | — | $0 | 84,126 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise deriv | 2024-07-23 | 2024-07-25 | 136,124 | — | $0 | 189,147 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2024-07-23 | 2024-07-25 | 50,000 | $25.05 | $1.25M | 126,061 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2024-07-23 | 2024-07-25 | 23,075 | $23.25 | $536.5K | 176,061 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | M Exercise | 2024-07-23 | 2024-07-25 | 136,124 | $1.59 | $216.4K | 199,136 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals In | S Sale | 2024-07-23 | 2024-07-25 | 63,049 | $27.01 | $1.70M | 63,012 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2024-04-08 | 2024-04-08 | 9,992 | — | $0 | 34,401 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2024-04-08 | 2024-04-08 | 9,992 | — | $0 | 67,087 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2024-04-08 | 2024-04-08 | 4,075 | $17.90 | $72.9K | 63,012 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2024-04-04 | 2024-04-08 | 129,750 | — | $0 | 129,750 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2024-04-04 | 2024-04-08 | 20,000 | — | $0 | 20,000 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2024-04-04 | 2024-04-08 | 24,950 | — | $0 | 44,393 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2024-04-01 | 2024-04-03 | 6,482 | — | $0 | 19,443 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2024-04-01 | 2024-04-03 | 1,903 | $19.70 | $37.5K | 57,095 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2024-04-01 | 2024-04-03 | 6,482 | — | $0 | 58,998 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2024-03-07 | 2024-03-11 | 65,012 | $21.02 | $1.37M | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2024-03-06 | 2024-03-06 | 5,582 | $21.00 | $117.2K | 65,012 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2024-03-04 | 2024-03-06 | 3,336 | $22.00 | $73.4K | 70,594 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2024-03-04 | 2024-03-06 | 9,406 | $21.31 | $200.4K | 73,930 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2023-09-02 | 2023-09-06 | 6,569 | — | $0 | 13,138 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2023-09-02 | 2023-09-06 | 2,187 | $17.76 | $38.8K | 52,516 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2023-09-02 | 2023-09-06 | 6,569 | — | $0 | 54,703 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2023-09-01 | 2023-09-06 | 9,992 | — | $0 | 29,975 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2023-09-01 | 2023-09-06 | 25,925 | — | $0 | 25,925 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2023-09-01 | 2023-09-06 | 155,500 | — | $0 | 155,500 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2023-09-01 | 2023-09-06 | 4,432 | $17.76 | $78.7K | 48,134 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2023-09-01 | 2023-09-06 | 9,992 | — | $0 | 52,566 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2023-04-10 | 2023-04-11 | 9,992 | — | $0 | 29,975 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2023-04-10 | 2023-04-11 | 9,992 | — | $0 | 45,507 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2023-04-10 | 2023-04-11 | 2,933 | $10.71 | $31.4K | 42,574 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2023-04-01 | 2023-04-03 | 25,925 | — | $0 | 25,925 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2023-04-01 | 2023-04-03 | 155,500 | — | $0 | 155,500 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2023-03-20 | 2023-03-20 | 12,002 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2023-03-20 | 2023-03-20 | 3,523 | $11.12 | $39.2K | 35,515 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2023-03-20 | 2023-03-20 | 12,002 | — | $0 | 39,038 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2023-03-16 | 2023-03-20 | 6,569 | — | $0 | 13,138 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2023-03-16 | 2023-03-20 | 1,929 | $11.46 | $22.1K | 27,036 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2023-03-16 | 2023-03-20 | 6,569 | — | $0 | 28,965 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2022-09-02 | 2022-09-06 | 6,569 | — | $0 | 19,707 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2022-09-02 | 2022-09-06 | 1,929 | $11.44 | $22.1K | 22,396 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2022-09-02 | 2022-09-06 | 6,569 | — | $0 | 24,325 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2022-09-01 | 2022-09-06 | 239,795 | — | $0 | 239,795 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2022-09-01 | 2022-09-06 | 39,967 | — | $0 | 39,967 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2022-04-07 | 2022-04-11 | 39,967 | — | $0 | 39,967 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2022-04-07 | 2022-04-11 | 239,795 | — | $0 | 239,795 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2022-03-21 | 2022-03-23 | 18,555 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2022-03-21 | 2022-03-23 | 18,555 | — | $0 | 23,202 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2022-03-21 | 2022-03-23 | 5,446 | $10.98 | $59.8K | 17,756 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2022-03-16 | 2022-03-18 | 6,569 | — | $0 | 19,707 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | F Tax w/h | 2022-03-16 | 2022-03-18 | 1,922 | $10.13 | $19.5K | 4,647 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2022-03-16 | 2022-03-18 | 6,569 | — | $0 | 6,569 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2021-09-02 | 2021-09-07 | 26,276 | — | $0 | 26,276 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2021-09-02 | 2021-09-07 | 157,658 | — | $0 | 157,658 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2021-03-20 | 2021-03-23 | 12,002 | — | $0 | 12,002 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2021-03-20 | 2021-03-23 | 18,555 | — | $0 | 18,555 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2021-03-16 | 2021-03-18 | 157,658 | — | $0 | 157,658 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2021-03-16 | 2021-03-18 | 26,276 | — | $0 | 26,276 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2021-02-10 | 2021-02-10 | 1,600 | — | $0 | 325,271 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2021-02-10 | 2021-02-10 | 1,600 | $1.59 | $2.5K | 1,600 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2021-02-10 | 2021-02-10 | 1,600 | $23.06 | $36.9K | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2021-02-10 | 2021-02-10 | 1,137 | $23.07 | $26.2K | 83,336 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2021-02-09 | 2021-02-10 | 20,401 | — | $0 | 326,871 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2021-02-09 | 2021-02-10 | 20,401 | $1.59 | $32.4K | 20,401 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2021-02-09 | 2021-02-10 | 23,569 | $23.08 | $544.0K | 84,473 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2021-02-09 | 2021-02-10 | 20,401 | $23.04 | $470.0K | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2021-02-08 | 2021-02-10 | 4,924 | — | $0 | 347,272 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2021-02-08 | 2021-02-10 | 4,924 | $1.59 | $7.8K | 4,924 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2021-02-08 | 2021-02-10 | 4,924 | $23.00 | $113.3K | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2021-02-08 | 2021-02-10 | 4,528 | $23.00 | $104.1K | 108,042 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2020-10-12 | 2020-10-14 | 150,700 | — | $0 | 352,196 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2020-10-12 | 2020-10-14 | 150,700 | $1.59 | $239.6K | 150,700 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2020-10-12 | 2020-10-14 | 99,330 | $21.02 | $2.09M | 112,570 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2020-10-12 | 2020-10-14 | 150,700 | $21.02 | $3.17M | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise deriv | 2020-10-09 | 2020-10-14 | 872 | — | $0 | 502,896 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | M Exercise | 2020-10-09 | 2020-10-14 | 872 | $1.59 | $1.4K | 872 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2020-10-09 | 2020-10-14 | 872 | $21.00 | $18.3K | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2020-10-09 | 2020-10-14 | 670 | $21.00 | $14.1K | 211,900 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2020-09-10 | 2020-09-14 | 180,000 | — | $0 | 180,000 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2020-03-13 | 2020-03-17 | 180,000 | — | $0 | 180,000 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | S Sale | 2020-03-06 | 2020-03-10 | 33,115 | $20.00 | $662.3K | 212,570 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2019-09-17 | 2019-09-19 | 190,000 | — | $0 | 190,000 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2019-03-04 | 2019-03-06 | 187,000 | — | $0 | 187,000 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | A Award deriv | 2018-09-20 | 2018-09-24 | 125,000 | — | $0 | 125,000 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | C Conversion deriv | 2018-05-29 | 2018-05-29 | 428,203 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | C Conversion deriv | 2018-05-29 | 2018-05-29 | 71,967 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | C Conversion deriv | 2018-05-29 | 2018-05-29 | 428,203 | — | $0 | 1,526,160 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | C Conversion deriv | 2018-05-29 | 2018-05-29 | 63,922 | — | $0 | 0 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | C Conversion | 2018-05-29 | 2018-05-29 | 135,889 | — | $0 | 245,685 | SEC↗ |
| KNSA Kiniksa Pharmaceuticals, L | P Buy deriv | 2018-02-09 | 2018-05-29 | 63,922 | $15.64 | $999.7K | 63,922 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | A Award deriv | 2017-06-08 | 2017-09-22 | 11,000 | — | $0 | 11,000 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | A Award deriv | 2017-06-08 | 2017-06-12 | 11,000 | — | $0 | 11,000 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2017-05-24 | 2017-05-25 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SYRS Syros Pharmaceuticals, Inc | A Award deriv | 2016-09-15 | 2016-09-19 | 22,000 | — | $0 | 22,000 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2016-05-23 | 2016-05-25 | 30,000 | — | $0 | 30,000 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2015-09-25 | 2015-09-29 | 16,667 | — | $0 | 16,667 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | D To issuer deriv | 2015-06-22 | 2015-06-23 | 128,000 | — | $0 | 0 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | D To issuer deriv | 2015-06-22 | 2015-06-23 | 148,000 | — | $0 | 0 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | D To issuer deriv | 2015-06-22 | 2015-06-23 | 120,000 | — | $0 | 0 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | D To issuer deriv | 2015-06-22 | 2015-06-23 | 22,512 | — | $0 | 0 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | D To issuer deriv | 2015-06-22 | 2015-06-23 | 136,052 | — | $0 | 0 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | D To issuer | 2015-06-22 | 2015-06-23 | 72,000 | — | $0 | 0 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | D To issuer | 2015-06-22 | 2015-06-23 | 286 | — | $0 | 0 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | D To issuer | 2015-06-22 | 2015-06-23 | 1,031 | — | $0 | 72,000 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | A Award | 2015-06-05 | 2015-06-09 | 72,000 | — | $0 | 73,031 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise deriv | 2014-12-17 | 2014-12-19 | 31,448 | — | $0 | 136,052 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise deriv | 2014-12-17 | 2014-12-19 | 13,536 | — | $0 | 22,512 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise deriv | 2014-12-17 | 2014-12-19 | 5,016 | — | $0 | 0 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-12-17 | 2014-12-19 | 5,016 | $87.25 | $437.6K | 46,015 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-12-17 | 2014-12-19 | 4,488 | $87.26 | $391.6K | 27,991 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-12-17 | 2014-12-19 | 13,536 | $87.55 | $1.19M | 32,479 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-12-17 | 2014-12-19 | 26,960 | $90.06 | $2.43M | 1,031 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise | 2014-12-17 | 2014-12-19 | 31,448 | $23.00 | $723.3K | 51,031 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise | 2014-12-17 | 2014-12-19 | 5,016 | $3.52 | $17.7K | 19,583 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise | 2014-12-17 | 2014-12-19 | 13,536 | $1.70 | $23.0K | 14,567 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS | A Award deriv | 2014-07-17 | 2014-07-21 | 551 | — | $0 | 551 | SEC↗ |
| ICPT INTERCEPT PHARMACEUTICALS | A Award | 2014-07-17 | 2014-07-21 | 452 | — | $0 | 452 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | A Award deriv | 2014-06-04 | 2014-06-05 | 120,000 | — | $0 | 120,000 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise deriv | 2014-01-29 | 2014-01-30 | 50,971 | — | $0 | 5,016 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-01-29 | 2014-01-30 | 24,817 | $87.19 | $2.16M | 27,185 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-01-29 | 2014-01-30 | 400 | $91.58 | $36.6K | 1,031 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-01-29 | 2014-01-30 | 1,502 | $90.85 | $136.5K | 1,431 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-01-29 | 2014-01-30 | 5,600 | $89.27 | $499.9K | 2,933 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-01-29 | 2014-01-30 | 18,652 | $88.31 | $1.65M | 8,533 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise | 2014-01-29 | 2014-01-30 | 50,971 | $3.52 | $179.4K | 52,002 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise deriv | 2014-01-28 | 2014-01-30 | 6,106 | — | $0 | 0 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise deriv | 2014-01-28 | 2014-01-30 | 24,832 | — | $0 | 55,987 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise deriv | 2014-01-28 | 2014-01-30 | 20,391 | — | $0 | 36,048 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-01-28 | 2014-01-30 | 9,506 | $87.16 | $828.5K | 42,854 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-01-28 | 2014-01-30 | 32,609 | $88.38 | $2.88M | 10,245 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-01-28 | 2014-01-30 | 8,402 | $88.95 | $747.4K | 1,843 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise | 2014-01-28 | 2014-01-30 | 20,391 | $1.70 | $34.7K | 52,360 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise | 2014-01-28 | 2014-01-30 | 24,832 | $3.52 | $87.4K | 31,969 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise | 2014-01-28 | 2014-01-30 | 6,106 | $0.95 | $5.8K | 7,137 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2014-01-28 | 2014-01-30 | 812 | $90.10 | $73.2K | 1,031 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise deriv | 2013-07-29 | 2013-07-29 | 15,895 | — | $0 | 80,819 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2013-07-29 | 2013-07-29 | 15,895 | $47.39 | $753.3K | 1,031 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise | 2013-07-29 | 2013-07-29 | 15,895 | $3.52 | $56.0K | 16,926 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise deriv | 2013-07-26 | 2013-07-29 | 16,882 | — | $0 | 56,439 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise deriv | 2013-07-26 | 2013-07-29 | 35,308 | — | $0 | 96,714 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2013-07-26 | 2013-07-29 | 17,204 | $48.31 | $831.1K | 1,031 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise | 2013-07-26 | 2013-07-29 | 35,308 | $3.52 | $124.3K | 53,543 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | M Exercise | 2013-07-26 | 2013-07-29 | 16,882 | $1.70 | $28.7K | 70,425 | SEC↗ |
| GEVA SYNAGEVA BIOPHARMA CORP | S Sale | 2013-07-26 | 2013-07-29 | 52,190 | $47.91 | $2.50M | 18,235 | SEC↗ |